Cyclo (RGDyK)

Cyclo (RGDyK) is an inhibitor of Integrins used in studies of MAPK / ERK Signaling and NF-kB Signaling and related signaling programs. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and inflammatory transcriptional control and stress-responsive survival signaling in angiogenesis, cancer, and developmental biology models.

By inhibiting Integrins, Cyclo (RGDyK) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and inflammatory transcriptional control and stress-responsive survival signaling. This context is compatible with phosphorylation mapping, pathway-response, and growth assays and NF-kB reporter, cytokine, and inflammation assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In angiogenesis, cancer, and developmental biology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving Integrins
• Pathway perturbation studies connected to MAPK / ERK Signaling and NF-kB Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Phenotypic profiling in angiogenesis, cancer, and developmental biology models

Overall, Cyclo (RGDyK) is appropriate when a defined chemical perturbant is needed to connect Integrins with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, cancer, and developmental biology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.